Mineralys Therapeutics, Inc. (MLYS) Max Pain Analysis

Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.

Mineralys Therapeutics, Inc. (MLYS) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $1.77B, listed on NASDAQ, employing roughly 51 people, carrying a beta of 0.56 to the broader market. Mineralys Therapeutics, Inc. Led by Jon Congleton, public since 2023-02-10.

Snapshot as of Jun 30, 2026.

Spot Price

$26.86

Max Pain Strike

$30.00

Total OI

35.6K

As of Jun 30, 2026, Mineralys Therapeutics, Inc. (MLYS) max pain sits at $30.00, which is above the current spot price of $26.86 (11.7% away). Spot sits 11.7% above max pain - the gap is wide enough that the pinning effect alone is unlikely to close it; expect catalyst flow, positioning unwinds, or rebalancing to drive the actual price path before any expiration pull. MLYS sits in the lower-price band (spot $26.86), where $0.50-$2.50 strike spacing makes pin-to-strike effects easy to spot but per-contract dollar gamma is smaller. Total open interest across the listed chain is comparatively thin (35.6K contracts), so single-strike pinning is less reliable than it is for high-OI names. MLYS is currently in negative dealer gamma (-$295.6K), a regime that amplifies directional moves rather than damping them, weakening the pin-toward-max-pain bias. Max pain identifies the strike at which the aggregate dollar value of all outstanding options contracts would expire with the least total intrinsic value, a gravitational reference rather than a price target.

MLYS Strategy Implications at the Current Max Pain Level

With spot 11.7% from the $30.00 max-pain level and Mineralys Therapeutics, Inc. in a negative-gamma regime, where dealer hedging amplifies directional moves and weakens any pin, strategy selection turns on cycle position and dealer positioning. Iron condors and credit spreads centered near the max-pain strike capture the typical end-of-cycle convergence when the regime supports pinning; ratio backspreads or directional debit structures fit names where catalyst flow is likely to overwhelm the hedging-driven pull. The gamma-exposure page shows the per-strike dealer book that determines whether hedging will reinforce or fight the pin.

How to read the MLYS max-pain chart

The open-interest histogram above shows where Mineralys Therapeutics, Inc. call and put writers have stacked the most inventory. Strikes with elevated call OI act as overhead resistance when dealers are long-gamma (they sell rallies into the wall); strikes with elevated put OI act as support (dealers buy dips toward the wall). The max-pain strike is the single price at which the total cash payout to option holders is minimized - the lowest-pain price for the writers as a group. The max-pain strike sits at $30.00, 11.7% above spot. Net dealer gamma is negative at -$295.6K, so as spot moves dealers buy rallies and sell dips, mechanically amplifying realized volatility.

MLYS max-pain in context

Max pain is an end-of-cycle convergence signal, not an intraday compass. Cross-reference the level with the gamma-flip strike on the GEX page, the front-month ATM IV reading (currently 69.1%), and any catalyst risk on the calendar. Total listed OI on MLYS sits at 35.6K contracts; pin strength generally scales with this number, since heavier OI means more delta to hedge as spot drifts toward the strike. A pin can fail - earnings, FDA decisions, central-bank surprises, and other vol catalysts can rip spot past max pain regardless of where dealers want it. Use max pain to size risk-defined structures, not as a directional thesis.

Reading MLYS max-pain alongside dealer positioning

The clean version of the max-pain mechanism requires positive dealer gamma to enforce convergence; in a negative-gamma regime the same OI distribution can repel rather than attract spot. MLYS is currently in a negative-gamma regime, so dealer hedging amplifies rather than dampens directional moves - max-pain convergence is less likely without a separate stabilizing catalyst. The put/call OI ratio sits at 0.54; ratios above 1.0 indicate put-heavy positioning that typically marks supportive flow, ratios below 0.7 indicate call-heavy positioning often associated with breakouts. Combine the pin level with the gamma-flip level and the implied move to model out where spot is likely to anchor through expiration.

Learn how max pain is reported and how to read the data →

Frequently asked MLYS max pain analysis questions

What is the current MLYS max pain strike?

As of Jun 30, 2026, Mineralys Therapeutics, Inc. (MLYS) max pain sits at $30.00, which is 11.7% above the current spot price of $26.86. Max pain identifies the strike at which aggregate option-buyer payouts at expiration are minimized; it is a gravitational reference, not a price target. A 11.7% gap is wide enough that the pinning effect alone is unlikely to close it; expect catalyst flow, positioning unwinds, or rebalancing to drive the price path before any expiration pull.

Does MLYS pin to its max pain strike at expiration?

MLYS is currently in negative dealer gamma, a regime that amplifies directional moves rather than damping them. The pin-toward-max-pain bias weakens here because dealer hedging adds momentum rather than mean reversion. Total open interest across MLYS (35.6K contracts) is one input to how plausible a clean pin is - heavier total OI concentrated at fewer strikes raises the probability; thin OI spread across many strikes lowers it. Pinning is strongest in heavily-traded names with large open-interest concentrations at high-OI strikes during the final week of an OPEX cycle. Whether MLYS actually pins on a given expiration depends on the OI distribution, the dealer-gamma sign, and the absence of catalyst-driven moves that overwhelm hedging-driven flow.

How is MLYS max pain calculated?

Max pain is computed by summing the dollar value of all in-the-money options at each candidate settlement strike across listed expirations, then selecting the strike that minimizes total intrinsic-value payout to option buyers. The calculation uses the full open-interest distribution and weighs both calls and puts. MLYS put/call OI ratio is 0.69 - call-heavy, which biases the max-pain calculation toward strikes above current spot when the call OI concentrates there.